Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
The novel ADC D3-GPC2-PBD was developed for neuroblastoma linking to a specific glypican 2 targeting antibody to the DNA damaging pyrrolobenzodiazepine dimers. This ADC was used in panel of neuroblastoma patient-derived xenografts.
Olaptesed Pegol Wins FDA Fast Track Designation in Brain Cancer
April 3rd 2024The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.
Read More